Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06641089 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorEnrollment closed, study ongoingCompletion pushed from Jan 15, 2027 to Sep 13, 2027 · Primary completion date: Jan 15, 2027 to Jan 4, 2027 · Eligibility criteria expanded, about 14 words · 1 moreShow 4 more changesShow less
Completion pushed from Jan 15, 2027 to Sep 13, 2027
Primary completion date: Jan 15, 2027 to Jan 4, 2027
Eligibility criteria expanded, about 14 words
Site details revised at 143 of 143 sites
MinorStudy sites: 142 to 143v14
MinorTrial sites expanded: 139 → 142 locationsv13
MinorStudy sites: 138 to 139v12
MinorStudy sites: 136 to 138v11
MinorStudy sites: 135 to 136v10
MinorTrial sites expanded: 128 → 135 locationsv9
MinorStudy sites: 126 to 128v8
MinorStudy sites: 123 to 126v7
MinorStudy sites: 121 to 123Eligibility criteria expanded, about 5 wordsv6Show 1 more changeShow less
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 3v2Show 1 more changeShow less
Study sites: 0 to 3
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.